Immunic Secures Patent for Vidofludimus Calcium, Advancing MS Treatment Efforts

Immunic Strengthens Patent Portfolio for Vidofludimus Calcium in Multiple Sclerosis Treatment

Immunic, Inc., a biotechnology company specializing in orally administered therapies for chronic inflammatory and autoimmune diseases, recently secures a Notice of Allowance for its fifth U.S. patent concerning vidofludimus calcium (IMU-838). This patent specifically pertains to dosing strengths from 10 mg to 45 mg designed for treating progressive multiple sclerosis (PMS), which encompasses primary progressive MS (PPMS) and secondary progressive MS (SPMS). With this new patent, Immunic enhances its intellectual property protections, extending their coverage until 2041, and potentially beyond, thus solidifying its competitive edge in the rapidly evolving landscape of MS therapies.

The significance of this patent is underscored by the recent findings from the phase 2 CALLIPER trial, which demonstrate vidofludimus calcium's potential in delaying the progression of disability in PMS patients. The trial indicates a promising reduction in both thalamic brain volume loss and the occurrence of new or enlarging T2 lesions. These results not only reinforce the drug’s neuroprotective capabilities but also position it favorably for pivotal phase 3 trials, as the 24-week confirmed disability worsening (24wCDW) endpoint is deemed an acceptable measure for further clinical evaluation. Immunic is actively engaging with healthcare authorities to determine the next steps for advancing their clinical development efforts.

Immunic's comprehensive intellectual property strategy is pivotal as it navigates the competitive landscape of multiple sclerosis treatments, where unmet medical needs remain substantial. The company has successfully secured multiple patents across the U.S. and Europe, covering various facets related to vidofludimus calcium, including its composition and specific dosing regimens utilized in clinical trials. This robust patent portfolio positions Immunic to address significant challenges in treating progressive forms of MS, enhancing their ability to provide innovative solutions for patients suffering from this debilitating condition.

In a related note, CEO Daniel Vitt, Ph.D., emphasizes the importance of this patent in the context of the positive trial results, highlighting the company's commitment to progressing its clinical pipeline. With the ongoing development of vidofludimus calcium, Immunic remains focused on meeting the pressing demands of patients affected by progressive multiple sclerosis, aiming to deliver a transformative impact on their quality of life.